Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations

被引：0

作者：

Stuerzebecher, Paulina Elena ^{[1
]}

Laufs, Ulrich ^{[1
]}

机构：

[1] Univ Klinikum Leipzig, Klinik & Poliklin Kardiol, Liebigstr 20, D-04103 Leipzig, Germany

来源：

CURRENT OPINION IN LIPIDOLOGY | 2024年 / 35卷 / 04期

关键词：

familial hypercholesterolemia; myocardial infarction; proprotein convertase subtilisin/kexin type 9; sex; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; PCSK9; INHIBITORS; SEX-DIFFERENCES; DOUBLE-BLIND; EVOLOCUMAB; ALIROCUMAB; EFFICACY; SAFETY; INCLISIRAN; RATIONALE;

D O I：

10.1097/MOL.0000000000000935

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Purpose of reviewMonoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations.Recent findingsLong-term data on the use of evolocumab and alirocumab shows persisting low- density lipoprotein cholesterol (LDL-C) lowering and good tolerability. PCSK9 inhibitors are effective and safe in both sexes, in pediatric patients as well as in the elderly. Initiation of PCSK9 mAb during acute myocardial infarction is safe and leads to beneficial morphological plaque changes. The PCSK9 inhibitors evolocumab, alirocumab and inclisiran lower LDL-C in patients with heterozygous familial hypercholesterolemia (FH), while the response of patients with homozygous FH is heterogeneous. New areas of application beyond lipid lowering are currently investigated.SummaryPCSK9 inhibitors are safe, well tolerated, and effective in primary and secondary prevention in a wide range of patient populations.

引用

页码：179 / 186

页数：8

共 59 条

[1] Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial [J].

Bar, Sarah ;

Kavaliauskaite, Raminta ;

Otsuka, Tatsuhiko ;

Ueki, Yasushi ;

Haner, Jonas D. ;

Siontis, George C. M. ;

Stortecky, Stefan ;

Shibutani, Hiroki ;

Temperli, Fabrice ;

Kaiser, Christoph ;

Iglesias, Juan F. ;

van Geuns, Robert Jan ;

Daemen, Joost ;

Spirk, David ;

Engstrom, Thomas ;

Lang, Irene ;

Windecker, Stephan ;

Koskinas, Konstantinos C. ;

Losdat, Sylvain ;

Raber, Lorenz .

EUROINTERVENTION, 2023, 19 (04) :E286-+

[2] Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial [J].

Blom, Dirk J. ;

Harada-Shiba, Mariko ;

Rubba, Paolo ;

Gaudet, Daniel ;

Kastelein, John J. P. ;

Charng, Min-Ji ;

Pordy, Robert ;

Donahue, Stephen ;

Ali, Shazia ;

Dong, Yuping ;

Khilla, Nagwa ;

Banerjee, Poulabi ;

Baccara-Dinet, Marie ;

Rosenson, Robert S. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) :131-142

[3] Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial [J].

Bohula, Erin A. ;

Marston, Nicholas A. ;

Ruzza, Andrea ;

Murphy, Sabina A. ;

Ferrari, Gaetano M. De ;

Diaz, Rafael ;

Leiter, Lawrence A. ;

Elliott-Davey, Mary ;

Wang, Huei ;

Bhatia, Ajay K. ;

Giugliano, Robert P. ;

Sabatine, Marc S. .

AMERICAN HEART JOURNAL, 2024, 269 :179-190

[4] Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study [J].

Bruckert, Eric ;

Caprio, Sonia ;

Wiegman, Albert ;

Charng, Min-Ji ;

Zarate-Morales, Cezar A. ;

Baccara-Dinet, Marie T. ;

Manvelian, Garen ;

Ourliac, Anne ;

Scemama, Michel ;

Daniels, Stephen R. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42 (12) :1447-1457

[5] Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study [J].

Cainzos-Achirica, Miguel ;

Quispe, Renato ;

Mszar, Reed ;

Dudum, Ramzi ;

Al Rifai, Mahmoud ;

Erbel, Raimund ;

Stang, Andreas ;

Jockel, Karl-Heinz ;

Lehmann, Nils ;

Schramm, Sara ;

Schmidt, Borge ;

Toth, Peter P. ;

Rana, Jamal S. ;

Lima, Joao A. C. ;

de Vasconcellos, Henrique Doria ;

Lloyd-Jones, Donald ;

Joshi, Parag H. ;

Ayers, Colby ;

Khera, Amit ;

Blaha, Michael J. ;

Greenland, Philip ;

Nasir, Khurram .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (16)

[6] Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry [J].

Cordero, Alberto ;

Fernandez del Olmo, M. Rosa ;

Cortez Quiroga, Gustavo A. ;

Romero-Menor, Cesar ;

Facila, Lorenzo ;

Seijas-Amigo, Jose ;

Fornovi, Aisa ;

Murillo, Juan R. ;

Rodriguez-Manero, Moises ;

Bello Mora, Maria C. ;

Valle, Alfonso ;

Miriam, Sandin ;

Pamias, Roman F. ;

Baneras, Jordi ;

Garcia, Pedro B. ;

Clemente Lorenzo, Maria M. ;

Sanchez-Alvarez, Sergio ;

Lopez-Rodriguez, Luis ;

Gonzalez-Juanatey, Jose R. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (04) :523-529

[7] Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study [J].

de Isla, Leopoldo Perez L. ;

Diaz-Diaz, Jose J. ;

Romero, Manuel ;

Muniz-Grijalvo, Ovidio D. ;

Mediavilla, Juan ;

Argueeso, Rosa F. ;

Munoz-Torrero, Juan Sanchez ;

Rubio, Patricia ;

Alvarez-Banos, Pilar ;

Ponte, Paola ;

Manas, Dolores ;

Gutierrez, Lorena Suarez ;

Cepeda, Jose Maria ;

Casanas, Marta ;

Fuentes, Francisco ;

Guijarro, Carlos ;

Barba, Miguel Angel ;

Cerezo, Adriana Saltijeral ;

Padro, Teresa ;

Mata, Pedro .

CIRCULATION, 2023, 147 (19) :1436-1443

[8] Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J].

Ference, Brian A. ;

Ginsberg, Henry N. ;

Graham, Ian ;

Ray, Kausik K. ;

Packard, Chris J. ;

Bruckert, Eric ;

Hegele, Robert A. ;

Krauss, Ronald M. ;

Raal, Frederick J. ;

Schunkert, Heribert ;

Watts, Gerald F. ;

Boren, Jan ;

Fazio, Sergio ;

Horton, Jay D. ;

Masana, Luis ;

Nicholls, Stephen J. ;

Nordestgaard, Borge G. ;

van de Sluis, Bart ;

Taskinen, Marja-Riitta ;

Tokgozoglu, Lale ;

Landmesser, Ulf ;

Laufs, Ulrich ;

Wiklund, Olov ;

Stock, Jane K. ;

Chapman, M. John ;

Catapano, Alberico L. .

EUROPEAN HEART JOURNAL, 2017, 38 (32) :2459-2472

[9] Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE [J].

Gaba, Prakriti ;

O'Donoghue, Michelle L. ;

Park, Jeong-Gun ;

Wiviott, Stephen D. ;

Atar, Dan ;

Kuder, Julia F. ;

Im, KyungAh ;

Murphy, Sabina A. ;

De Ferrari, Gaetano M. ;

Gaciong, Zbigniew A. ;

Toth, Kalman ;

Gouni-Berthold, Ioanna ;

Lopez-Miranda, Jose ;

Schiele, Francois ;

Mach, Francois ;

Flores-Arredondo, Jose H. ;

Lopez, J. Antonio G. ;

Elliott-Davey, Mary ;

Wang, Bei ;

Monsalvo, Maria Laura ;

Abbasi, Siddique ;

Giugliano, Robert P. ;

Sabatine, Marc S. .

CIRCULATION, 2023, 147 (16) :1192-1203

[10] Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry [J].

Galema-Boers, Annette M. H. ;

Mulder, Janneke W. C. M. ;

Steward, Kim ;

van Lennep, Jeanine E. Roeters .

ATHEROSCLEROSIS, 2023, 384

← 1 2 3 4 5 6 →